APL Q4 FY26 results at a glance
ASSTON PHARMACEUTICALS LIMITED Q4 FY26 key results metrics| Quarter | Q4 FY26 |
|---|
| Quarter ended | 31 Mar 2026 |
|---|
| Revenue | ₹10.05 cr |
|---|
| Revenue YoY | +10.9% |
|---|
| Operating profit | -₹3.05 cr |
|---|
| Operating margin | -30.4% |
|---|
| Net profit | ₹0.48 cr |
|---|
| Net profit YoY | -75.3% |
|---|
| Net profit QoQ | -75.3% |
|---|
| Net margin | 4.8% |
|---|
| Basic EPS | ₹1.14 |
|---|
| TTM revenue | — |
|---|
| TTM net profit | — |
|---|
| TTM net margin | — |
|---|
APL Q4 FY26 results: what the numbers say
ASSTON PHARMACEUTICALS LIMITED (APL) has reported its Q4 FY26 results for the quarter ended 2026-03-31. The company posted revenue of ₹10.05 cr and a net profit of ₹0.48 cr, translating into earnings per share of ₹1.14.
Compared with the same quarter a year earlier, revenue grew by +10.9% and net profit declined sharply by -75.3%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at -₹3.05 cr, an operating margin of -30.4% versus 34.8% a year ago — a contraction of 65.1 percentage points.
APL quarter-wise results table
Revenue
₹10.05 cr
+10.9% YoY
Net profit
₹0.48 cr
-75.3% YoY
Operating profit
-₹3.05 cr
-196.8% YoY
ASSTON PHARMACEUTICALS LIMITED (APL) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q4 FY262026-03-31 | ₹10.05 cr | -₹3.05 cr | ₹0.48 cr | -30.4% | 4.8% | ₹1.14 | -75.3% | -75.3% |
| Q4 FY252025-03-31 | ₹9.07 cr | ₹3.15 cr | ₹1.95 cr | 34.8% | 21.5% | ₹2.29 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
APL quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
ASSTON PHARMACEUTICALS LIMITED quarterly income statement| Particulars | Q4 FY262026-03-31 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹10.05 cr | ₹9.07 cr |
|---|
| Total expenses | ₹13.11 cr | ₹5.92 cr |
|---|
| Gross profit | ₹1.65 cr | ₹4.83 cr |
|---|
| Operating profit (EBIT) | -₹3.05 cr | ₹3.15 cr |
|---|
| Operating margin | -30.4% | 34.8% |
|---|
| Interest cost | ₹0.36 cr | ₹0.53 cr |
|---|
| Profit before tax | ₹1.22 cr | ₹2.56 cr |
|---|
| Tax expense | ₹0.74 cr | ₹0.6 cr |
|---|
| Effective tax rate | 60.4% | 23.7% |
|---|
| Net profit (PAT) | ₹0.48 cr | ₹1.95 cr |
|---|
| Net profit margin | 4.8% | 21.5% |
|---|
| Basic EPS | ₹1.14 | ₹2.29 |
|---|
| Diluted EPS | ₹1.14 | ₹2.29 |
|---|
APL results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q4 FY26 | Q4 FY25 |
|---|
| Revenue YoY | +10.9% | — |
|---|
| Revenue QoQ | +10.9% | — |
|---|
| Operating profit YoY | -196.8% | — |
|---|
| Operating profit QoQ | -196.8% | — |
|---|
| Net profit YoY | -75.3% | — |
|---|
| Net profit QoQ | -75.3% | — |
|---|
| EPS YoY | -50.3% | — |
|---|
| EPS QoQ | -50.3% | — |
|---|
APL annual results history
Full-year performance for ASSTON PHARMACEUTICALS LIMITED, useful for reading each quarter in context.
ASSTON PHARMACEUTICALS LIMITED annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹25.47 cr | ₹25.04 cr | ₹15.59 cr | ₹6.54 cr |
|---|
| Total expenses | ₹25.19 cr | ₹18.65 cr | ₹12.21 cr | ₹4.97 cr |
|---|
| Gross profit | ₹8.06 cr | ₹10.9 cr | ₹5.83 cr | ₹3.19 cr |
|---|
| Operating profit (EBIT) | ₹0.27 cr | ₹6.39 cr | ₹3.37 cr | ₹1.57 cr |
|---|
| Operating margin | 1.1% | 25.5% | 21.6% | 24.0% |
|---|
| Interest cost | ₹0.62 cr | ₹0.8 cr | ₹0.9 cr | ₹0.68 cr |
|---|
| Profit before tax | ₹4.59 cr | ₹5.02 cr | ₹1.82 cr | ₹1.41 cr |
|---|
| Tax expense | ₹0.73 cr | ₹1.16 cr | ₹0.46 cr | ₹0.36 cr |
|---|
| Effective tax rate | 15.9% | 23.2% | 25.1% | 25.2% |
|---|
| Net profit (PAT) | ₹3.87 cr | ₹3.85 cr | ₹1.36 cr | ₹1.06 cr |
|---|
| Net profit margin | 15.2% | 15.4% | 8.7% | 16.2% |
|---|
| Basic EPS | — | ₹4.53 | ₹1.60 | ₹1.24 |
|---|
| Diluted EPS | — | ₹4.53 | ₹1.60 | ₹1.24 |
|---|
Revenue trend and demand read-through
Topline for Q4 FY26 came in at ₹10.05 cr against ₹9.07 cr in Q4 FY25, and ₹9.07 cr in the preceding Q4 FY25 quarter.
On a sequential basis revenue grew +10.9%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹13.11 cr, or 130.4% of revenue, with operating profit declined -196.8% year on year.
Margins, tax and profitability
Net profit of ₹0.48 cr works out to a net margin of 4.8% compared with 21.5% in the year-ago quarter. Margin pressure of this kind usually reflects higher input costs, pricing competition, or a heavier interest and depreciation load.
Below the operating line, ASSTON PHARMACEUTICALS LIMITED reported profit before tax of ₹1.22 cr, a tax charge of ₹0.74 cr (effective rate 60.4%), interest cost of ₹0.36 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹1.95 cr in Q4 FY25 to ₹0.48 cr in Q4 FY26, a change of -75.3%.
Trailing twelve months and annual context
On a full-year basis, FY26 revenue was ₹25.47 cr with net profit of ₹3.87 cr and EPS of —, versus the prior year where revenue grew +1.7% and profit grew +0.3%.
What to watch in the next APL quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
ASSTON PHARMACEUTICALS LIMITED has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
APL results coverage
No results report published for APL yet — our desk covers each quarter within minutes of the filing.
APL quarterly results FAQs
What were ASSTON PHARMACEUTICALS LIMITED (APL) Q4 FY26 results?
In Q4 FY26 (quarter ended 31 Mar 2026), ASSTON PHARMACEUTICALS LIMITED reported revenue of ₹10.05 cr and net profit of ₹0.48 cr, a change of -75.3% year on year on +10.9% revenue growth. EPS stood at ₹1.14.
What is APL profit margin in Q4 FY26?
ASSTON PHARMACEUTICALS LIMITED posted a net profit margin of 4.8% and an operating margin of -30.4% in Q4 FY26. On a trailing twelve-month basis, revenue is — and net profit —.
Did APL results beat the previous quarter?
ASSTON PHARMACEUTICALS LIMITED net profit changed -75.3% quarter on quarter, from ₹1.95 cr in Q4 FY25 to ₹0.48 cr in Q4 FY26.
When are ASSTON PHARMACEUTICALS LIMITED (APL) quarterly results?
ASSTON PHARMACEUTICALS LIMITED has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see APL latest quarterly results?
Results coverage for APL will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the APL stock page.
What is ASSTON PHARMACEUTICALS LIMITED annual revenue and profit?
For FY26, ASSTON PHARMACEUTICALS LIMITED reported full-year revenue of ₹25.47 cr and net profit of ₹3.87 cr, with EPS of —.
How many quarterly results has APL declared recently?
Past results dates for APL will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
